MARTINSRIE, GERMANY and MUNICH, GERMANY--(Marketwire - December 06, 2012) - MorphoSys AG /
MorphoSys Strengthens Patent Position on anti-CD38 Cancer Program MOR202
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today
US Patent and Trademark Office (USPTO) has granted a patent covering the
Company's cancer compound MOR202. The new patent (US 8,263,746) covers
functional properties of anti-CD38 antibodies and provides additional
protection for MorphoSys's HuCAL antibody MOR202. The newly issued patent
to the US patent granted earlier this year covering the antibody's protein
sequence as well as pharmaceutical compositions comprising the same.
the two patent families provide strong intellectual property protection for
MOR202 program. The new patent has a scheduled expiry date in 2025, not
including any potential patent office or regulatory extensions.
Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG, commented:
"Antibodies targeting CD38 are gathering increased interest from the
pharmaceutical industry as a new potential treatment option in multiple
and other forms of leukemia. As with our other proprietary programs, our
to build a rich scientific, medical and commercial package around MOR202 in
order to lay the groundwork for future partnering. This new patent widens
scope of our patent position around the MOR202 program by covering the
functional aspects of anti-CD38 antibodies in addition to protecting the
individual antibody sequence."
MOR202 is a fully human HuCAL antibody directed against CD38, a therapeutic
target for the treatment of multiple myeloma and certain forms of leukemia.
fully human HuCAL-antibody is currently being tested in a phase 1/2a trial*
patients with relapsed/refractory multiple myeloma.
*Supported by the German Federal Ministry of Education and Research as part
Munich's leading edge cluster m4 - Personalized medicine and targeted
MorphoSys developed HuCAL, the most successful antibody library technology
the pharmaceutical industry. By successfully applying this and other
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
company's AbD Serotec unit uses HuCAL and other antibody technologies to
generate superior monoclonal antibodies for research and diagnostic
Together with its pharmaceutical partners, MorphoSys has built a
pipeline of more than 70 human antibody drug candidates for the treatment
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few.
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow.
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular
about MorphoSys, visit http://www.morphosys.com
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®,
RapMAT®, arYla®, Ylanthia®
and 100 billion high potentials® are registered trademarks of
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a
of MorphoSys AG.
This communication contains certain forward-looking statements concerning
MorphoSys group of companies. The forward-looking statements contained
represent the judgment of MorphoSys as of the date of this release and
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements
far as the wording of the relevant press release is concerned.
Media Release (PDF):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE